Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Dec 2005

Goetz Matthew P, Rae James M, Suman Vera J, Safgren Stephanie L, Ames Matthew M, Visscher Daniel W, Reynolds Carol, Couch Fergus J, Lingle Wilma L, Flockhart David A, Desta Zeruesenay, Perez Edith A, Ingle James N

Abstract excerpt

PURPOSE: Polymorphisms in tamoxifen metabolizing genes affect the plasma concentration of tamoxifen metabolites, but their effect on clinical outcome is unknown. METHODS: We determined cytochrome P450 (CYP)2D6 (*4 and *6) and CYP3A5 (*3) genotype from paraffin-embedded tumor samples and buccal cells (living patients) in tamoxifen-treated women enrolled onto a North Central Cancer Treatment Group adjuvant breast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 CYP3A

Share to Cytochrome P-450 Enzyme System

Share to Neoplasm Recurrence, Local

Share to Pharmacogenetics

Share to Tamoxifen

Source

Identifiers

PMID: 16361630
DOI: 10.1200/JCO.2005.03.3266

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.PMID 16361630Read ↗

CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.Semantic proximity Read ↗

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.Semantic proximity Read ↗

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.Semantic proximity Read ↗

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.Semantic proximity Read ↗

CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons LearnedSemantic proximity Read ↗

Association Analysis among Tamoxifen Metabolites and Genetic Polymorphisms in Hormone-Dependent Chilean Breast Cancer Patients: A Preliminary StudySemantic proximity Read ↗

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.Semantic proximity Read ↗

Personalized tamoxifen: a step closer but miles to go.Semantic proximity Read ↗

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.Semantic proximity Read ↗

Pharmacogenomics of tamoxifen therapy.Semantic proximity Read ↗

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial.Semantic proximity Read ↗

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.